Your doctor may prescribe this drug if you have already tried other medications to treat your specific cancer. Libtayo is a biologic drug and belongs to a group of drugs called programmed death ...

Results demonstrated that treatment with Libtayo reduced the risk of death by 32% compared with chemotherapy. The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced topline data from a pivotal, single-arm, open-label trial for the PD-1 inhibitor Libtayo in patients with advanced basal cell ...

Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials ...

The Food and Drug Administration has approved first-line Libtayo (cemiplimab-rwlc) monotherapy for patients with advanced non-small cell lung cancer with a PD-L1 expression of 50% or greater. The Food ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone ...